Merck KGaA's (MKGAF.PK) Erbitux treatment helped patients with metastatic colon cancer live around four months longer than Roche's Avastin in a head-to-head study. However, the overall response rate, as measured by tumor shrinkage, was the about same, as was the amount of time it took for the disease to worsen. A larger trial of the drugs is due to take place next year. Merck's U.S. partners in Erbitux are Eli Lilly (LLY) and Bristol-Myers Squibb (BMY). The findings were presented at the annual meeting of American Society of Clinical Oncology.
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs